Digital cognitive behavioral therapy for insomnia (dCBT-I) improves sleep onset latency in chronic insomnia patients, with effects comparable to zolpidem at 5 weeks and sustained at 10 weeks.
In a small exploratory RCT, a 5-week dCBT-I app reduced subjective sleep onset latency (sSOL) by -20.65 min at Week 5, similar to zolpidem (-22.42 min, p=0.7729). At Week 10 follow-up, dCBT-I showed sustained improvement (-29.02 min) while zolpidem showed slight recurrence (-16.19 min). No treatment-related adverse events occurred in the dCBT-I group.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Digital cognitive behavioral therapy for insomnia (dCBT-I) improves sleep onset latency in chronic insomnia patients, with effects comparable to zolpidem at 5 weeks and sustained at 10 weeks. The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Digital cognitive behavioral therapy for insomnia (dCBT-I) improves sleep onset latency in chronic insomnia patients, with effects comparable to zolpidem at 5 weeks and sustained at 10 weeks.
This conclusion is most relevant to: Patients with chronic sleep-onset insomnia who remained symptomatic after 4-week screening following sleep hygiene education (N=24).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Efficacy and safety of a novel digital cognitive behavioral therapy for insomnia application versus zolpidem: An exploratory randomized controlled trial. (Sleep medicine, 2026) —
How It Works
The proposed biological pathway:
- ▸dCBT-I targets dysfunctional beliefs and attitudes about sleep
- ▸Provides structured behavioral interventions (e.g., stimulus control, sleep restriction) via app
- ▸Improves sleep onset latency over 5 weeks
- ▸Effects maintained at 10-week follow-up, with greater improvement in dysfunctional beliefs
Who Might Benefit
Evidence fit by population:
- ▸Patients with chronic sleep-onset insomnia who remained symptomatic after 4-week screening following sleep hygiene education (N=24)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Small sample size (N=24) leading to underpowered study
- ▸Exploratory design, not confirmatory
- ▸High dropout rate (dCBT-I group n=9 at Week 10, zolpidem n=12)
- ▸No blinding for the dCBT-I group (likely unblinded)
Frequently Asked Questions
How does dCBT-I compare to zolpidem for insomnia?▼
At 5 weeks, both dCBT-I and zolpidem significantly reduced sleep onset latency with no significant difference between groups. However, at 10-week follow-up, dCBT-I maintained improvement while zolpidem showed slight recurrence.
Is dCBT-I safe?▼
No treatment-related adverse events were reported in the dCBT-I group, while one case of daytime somnolence occurred in the zolpidem group.
What is the duration of the dCBT-I treatment?▼
The dCBT-I treatment lasted 5 weeks, with a 5-week post-treatment follow-up.
What is the primary outcome measured in this study?▼
The primary outcome was the change in subjective Sleep Onset Latency (sSOL) from baseline at Week 5.
References
- 1.Shimizu E, Sato D, Miyoshi M, Ebisu H, Takahashi K, Inaba Y, Inoue Y, Osao M, Takeshima M, Ogasawara M, Hirano Y, Hanaoka H. “Efficacy and safety of a novel digital cognitive behavioral therapy for insomnia application versus zolpidem: An exploratory randomized controlled trial..” Sleep medicine, 2026. PMID: 42623797 DOI: 10.1016/j.sleep.2026.109222